Newsletter | September 3, 2026

09.03.26 -- Real-Time Visibility Is Reshaping Outsourced Gene Therapy

Setting A New Standard For Biotech Program Visibility

Managing outsourced programs shouldn't mean dealing with fragmented spreadsheets and endless email chains to see where your project stands. By unifying your data into a single digital platform, you bring clear visibility to your programs for confident, informed decisions.

 

Best Practices For Building A Multi-Product Manufacturing

Building a multi-product ATMP facility? Master the HVAC configuration, contamination controls, and N+1 redundancy an operations-first approach demands. Connect with facility experts and plan your next expansion with confidence.

 

A Platform For Advanced AAV Analytics

Advanced AAV analytics use high-resolution multiplex platforms to assess genome integrity and capsid traits — improving accuracy, accelerating development, and strengthening regulatory quality control.

 

How Real-Time Visibility Is Changing Outsourced Gene Therapy Programs

Fragmented systems and delayed reporting slow decisions in outsourced gene therapy. A new operating model unifies execution, governance, and risk data into one live environment for continuous insight and tighter sponsor-CDMO coordination.

 

SOLUTIONS

With You From Preclinical Through Commercial Scale

Andelyn Biosciences is your full-spectrum gene therapy partner. Work with us from start to finish of your product or partner with us at any stage of your project – preclinical through commercial scale.

• Request Information

 

 

 

A New Player With A Long History

Leveraging more than 15 years in the field, Andelyn Biosciences provides custom development and manufacturing of AAV vectors for gene therapy as a full-service concept-to-commercialization cGMP CDMO.

• Request Information